Ruxolitinib

• Catalog Number: ACM941678495
• Product Name: Ruxolitinib
• CAS: 941678-49-5
• Category: Inhibitors
• Description: Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy.
• Synonyms: Ruxolitinib;(R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile;1H-Pyrazole-1-propanenitrile,.beta.-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-,(.beta.R)-;(3R)-3-(4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;(3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyriMidin-4-yl}-1H-pyrazol-1-yl)propanenitrile;INCB018424 (Ruxolitinib);Jakafi
• Molecular Weight: 306.371
• Molecular Formula: C₁₇H₁₈N₆
• Density: 1.40

Custom Q&A

What is the molecular formula of Ruxolitinib?

The molecular formula of Ruxolitinib is C17H18N6.

What are some synonyms for Ruxolitinib?

Some synonyms for Ruxolitinib include INCB018424 and Ruxolitinib (INCB018424).

What is the molecular weight of Ruxolitinib?

The molecular weight of Ruxolitinib is 306.4 g/mol.

What is the role of Ruxolitinib as?

Ruxolitinib has a role as an antineoplastic agent and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor.

What is the ChEBI identifier for Ruxolitinib?

The ChEBI identifier for Ruxolitinib is Ruxolitinib, formerly known as INCB018424 or INC424.

What is the mechanism of action of Ruxolitinib?

The mechanism of action of Ruxolitinib is as a Janus Kinase Inhibitor.

In what year was Ruxolitinib first approved by the FDA for the treatment of adult patients with myelofibrosis?

Ruxolitinib was first approved by the FDA in 2011 for the treatment of adult patients with myelofibrosis.

What is the InChIKey for Ruxolitinib?

The InChIKey for Ruxolitinib is HFNKQEVNSGCOJV-OAHLLOKOSA-N.

How is Ruxolitinib being investigated in the context of coronavirus disease 2019 (COVID-19)?

Ruxolitinib has been investigated to treat patients with COVID-19 accompanied by severe systemic hyperinflammation.

What is the molecular structure of Ruxolitinib?

The molecular structure of Ruxolitinib is a pyrazole substituted at position 1 by a 2-cyano-1-cyclopentylethyl group and at position 3 by a pyrrolo[2,3-d]pyrimidin-4-yl group.